Treatment of Tourette's syndrome with calcium antagonists.

abstract：:Monoamine oxidase type B (MAO-B) is the predominant isoform responsible for the metabolic breakdown of dopamine in the brain. Selective inhibition of brain MAO-B results in elevation of synaptosomal dopamine concentrations. Data have been reported regarding the selective MAO-B inhibitors, rasagiline and selegiline, fo...

journal_title：Clinical neuropharmacology

authors： Fernandez HH,Chen JJ

更新日期：2007-05-01 00:00:00

abstract：:Five of 24 (21%) normal men (volunteers) administered alpha-methyl-para-tyrosine (AMPT), a catecholamine-depleting agent, developed acute dystonic reactions. The finding that catecholamine depletion without receptor blockade is sufficient to cause acute dystonia suggests that a variety of neurotransmitter imbalances m...

journal_title：Clinical neuropharmacology

authors： McCann UD,Penetar DM,Belenky G

更新日期：1990-12-01 00:00:00

abstract：:Spinal cord injury (SCI) is a devastating and common neurologic disorder that has profound influences on modern society from physical, psychosocial, and socioeconomic perspectives. Accordingly, the present decade has been labeled the Decade of the Spine to emphasize the importance of SCI and other spinal disorders. Sp...

journal_title：Clinical neuropharmacology

authors： Dumont RJ,Okonkwo DO,Verma S,Hurlbert RJ,Boulos PT,Ellegala DB,Dumont AS

更新日期：2001-09-01 00:00:00

abstract：:Acute psychotic episodes represent critical situations during the course of schizophrenia. Olanzapine (OLZ), a second-generation antipsychotic, is efficacious in acute settings at dosages of 5 to 20 mg/d, and it can be considered a first-line treatment for patients with an acute episode of schizophrenia. The aim of th...

journal_title：Clinical neuropharmacology

authors： Mauri MC,Colasanti A,Rossattini M,Moliterno D,Baldi ML,Papa P

更新日期：2006-05-01 00:00:00

abstract：OBJECTIVE:To determine whether a history of depression predisposes hyperkinetic patients treated with tetrabenazine (TBZ) to a recurrence or worsening of this symptom. METHODS:We retrospectively reviewed the charts of 518 patients treated with TBZ to determine the frequency of depression and other adverse events. Char...

journal_title：Clinical neuropharmacology

authors： Kenney C,Hunter C,Mejia N,Jankovic J

更新日期：2006-09-01 00:00:00

abstract：:The main augmentation strategy in the treatment of obsessive-compulsive disorder (OCD) is the addition of low-dose dopamine antagonists, such as risperidone. However, the development of additional pharmacological therapeutics is necessary because some patients remain refractory to these strategies. In the present repo...

journal_title：Clinical neuropharmacology

authors： da Rocha FF,Correa H

更新日期：2011-07-01 00:00:00

abstract：:Glutamate is the predominant excitatory neurotransmitter of the basal ganglia, where it acts on ionotropic and metabotropic receptors. In the best studied of the basal ganglia disorders, Parkinson's disease, there is compelling evidence that the activities of glutamatergic pathways are altered. Of particular importanc...

journal_title：Clinical neuropharmacology

authors： Greenamyre JT

更新日期：2001-03-01 00:00:00

abstract：:A group of four monkeys was rendered parkinsonian with the toxin MPTP. They were then treated chronically with L-DOPA/benserazide 50/12.5 mg/kg given orally daily for 2 months. This dose produced a striking antiparkinsonian effect, but all animals manifested dyskinesia. A series of agents acting primarily on neurotran...

journal_title：Clinical neuropharmacology

authors： Gomez-Mancilla B,Bédard PJ

更新日期：1993-10-01 00:00:00

abstract：:Following oral administration in the fasting healthy subject, the mean maximum concentration of tianeptine is 334 +/- 79 ng/ml. Absorption of tianeptine from the tablet form is rapid and complete. Maximum plasma concentration is obtained by the first hour following administration (0.94 +/- 0.47 h). Absolute bioavailab...

journal_title：Clinical neuropharmacology

authors： Royer RJ,Albin H,Barrucand D,Salvadori-Failler C,Kamoun A

更新日期：1988-01-01 00:00:00

abstract：:Few studies have been published on the pharmacologic response to treatment of patients whose seizures begin after 40 years of age. The purpose of this study was to assess the impact of chronic pharmacotherapy on the seizure control of such patients. We retrospectively studied the seizure frequency recorded during a 12...

journal_title：Clinical neuropharmacology

authors： Hasegawa H,Kanner AM

更新日期：1995-02-01 00:00:00

abstract：BACKGROUND:Negative myoclonus is rarely seen in the clinical setting. It can be involved in some central nervous system pathologies. It has also been observed after antipsychotic treatment. CASE REPORTS:In this article, we will present 3 cases diagnosed with negative myoclonus in a 120-bed university-affiliated hospit...

journal_title：Clinical neuropharmacology

authors： Uzun Ö,Bolu A,Taşçi AB,Oğur B

更新日期：2020-01-01 00:00:00

abstract：:Antiepileptic drugs (AEDs) suppress seizures by selectively modifying the excitability of neurons and blocking seizure firing with minimal disturbance of nonepileptic activity. All AEDs have been shown to work by at least one of 3 main mechanisms of action: through modulation of voltage-gated ion channels, enhancement...

journal_title：Clinical neuropharmacology

authors： Biton V

更新日期：2007-07-01 00:00:00

abstract：:Dehydroepiandrosterone (DHEA) is an important neurosteroid and has demonstrated efficacy in the improvement of mood and energy. The authors previously reported the efficacy of DHEA augmentation in the management of negative, depressive, and anxiety symptoms of schizophrenia. To characterize further the effects of DHEA...

journal_title：Clinical neuropharmacology

authors： Strous RD,Maayan R,Kotler M,Weizman A

更新日期：2005-11-01 00:00:00

abstract：:Hypereosinophilia is asymptomatic but can induce organ damage, which may cause neurological system abnormalities. We recently encountered a 29-year-old woman with depressive episodes who had eosinophilia as well as hyperventilation attacks, tremor, insomnia, and arthralgia of extremities after receiving paroxetine tre...

journal_title：Clinical neuropharmacology

authors： Yasui-Furukori N,Sato Y,Kato H,Kaneko S

更新日期：2012-01-01 00:00:00

abstract：:Calcitonin gene-related peptide (CGRP) is a signaling neuropeptide released from activated trigeminal sensory afferents in headache and facial pain disorders. There are a handful of CGRP-targeted therapies currently in phase 3 studies for migraine acute treatment or prevention. Currently, 4 monoclonal antibodies targe...

journal_title：Clinical neuropharmacology

authors： Schuster NM,Rapoport AM

更新日期：2017-07-01 00:00:00

abstract：OBJECTIVES:To describe further the phenomenology of drug-induced psychosis (DIP) in patients with Parkinson disease (PD) and assess which items on two common psychosis rating instruments-the Brief Psychiatric Rating Scale (BPRS) and the Neuropsychiatric Inventory (NPI)-are the best measure of DIP by comparing them with...

journal_title：Clinical neuropharmacology

authors： Chou KL,Messing S,Oakes D,Feldman PD,Breier A,Friedman JH

更新日期：2005-09-01 00:00:00

abstract：:Intravenous injection of low doses of naloxone was found to reverse the respiratory depression induced by apomorphine in chloralose-anesthesized dogs. Similar results were obtained with haloperidol, whereas yohimbine remained ineffective. These data suggest that apomorphine depresses respiratory rate through a mechani...

journal_title：Clinical neuropharmacology

authors： Montastruc JL,Rascol O,Montastruc P

更新日期：1992-10-01 00:00:00

abstract：:Twelve-hour urinary excretion of 4-hydroxy-3-methoxymandelic acid (VMA), homovanillic acid (HVA), and 3-methoxy-4-hydroxyphenylglycol (MHPG) was studied in 20 premature infants, 8 without apnea and 12 with apnea. All infants were studied at 1-3 days of postnatal age (before apnea). Nonapneic infants were restudied at ...

journal_title：Clinical neuropharmacology

authors： Bhat AM,Scanlon JW,Lavenstein B,Chuang L,Karoum F

更新日期：1982-12-01 00:00:00

abstract：:trans-Dihydrolisuride, a partial dopamine receptor agonist, was tested for its effects on chorea in a double-blind, crossover clinical study in 10 patients with Huntington's disease. In eight patients, a neurophysiological evaluation was also performed. No reduction in choreic movements or improvement in voluntary mov...

journal_title：Clinical neuropharmacology

authors： Stocchi F,Carta A,Berardelli A,Antonini A,Argenta M,Formica A,Agnoli A

更新日期：1989-10-01 00:00:00

abstract：:We report the case of a 76-year-old, right-handed woman with progressive primary freezing of gait. Despite several therapeutic strategies, she continued to worsen to the point that she became confined to a wheelchair. Treatment with selegiline in doses up to 20 mg/d led to marked improvement of the gait disorder. This...

journal_title：Clinical neuropharmacology

authors： Zúñiga C,Lester J,Cersósimo MG,Díaz S,Micheli FE

更新日期：2006-01-01 00:00:00

abstract：:The purpose of this paper is to add to the growing number of reports about kleptomania occurring in relation to brain injury as well as to present the authors' findings regarding treatment strategies. The authors present two case reports of patients who developed the new onset of kleptomania after closed head trauma. ...

journal_title：Clinical neuropharmacology

authors： Aizer A,Lowengrub K,Dannon PN

更新日期：2004-09-01 00:00:00

abstract：:Obsessive-compulsive disorder (OCD) is a brain disorder with recognizable periods of onset, course, familial occurrence, epidemiology, phenomenology, and treatment response. Several manifestations of pathophysiology are beginning to be defined, although they may represent intermediate pathophysiology rather than prima...

journal_title：Clinical neuropharmacology

authors： Micallef J,Blin O

更新日期：2001-07-01 00:00:00

abstract：:In the United States, trazodone has shown efficacy comparable with tricyclic antidepressants. Trazodone's side-effect profile, however, is vastly superior to the older drugs. In cases of overdose, trazodone alone has not caused a single death. For depressed patients, starting with 150 mg/day of trazodone, preferably a...

journal_title：Clinical neuropharmacology

authors： Fabre LF

更新日期：1989-01-01 00:00:00

abstract：:The freely diffusible gaseous compound nitric oxide (NO) has recently been discovered to be an important cellular messenger in many organ systems throughout the body. The importance of NO as an intermediary in cell communication in the brain is highlighted by the fact that the excitatory amino acid glutamate, the most...

journal_title：Clinical neuropharmacology

authors： Karatinos J,Rosse RB,Deutsch SI

更新日期：1995-12-01 00:00:00

abstract：:Fluctuations in motor performance are the major problems in chronic management of Parkinson's disease. Most of these fluctuations reflect the decline of levodopa availability. As a consequence, levodopa dosage might be increased and the interdose interval progressively shortened. The postsynaptic dopamine receptors at...

journal_title：Clinical neuropharmacology

authors： Stocchi F,Patsalos PN,Berardelli A,Barbato L,Bonamartini A,Manfredi M,Ruggieri S

更新日期：1994-01-01 00:00:00

abstract：:This study reports the antidepressant efficacy and the safety of amineptine (Survector 100) in a national multicenter open clinical trial (32 hospital centers). Three hundred twenty-four patients with depressive disorders, selected according to DSM-III Diagnostic Criteria and INSERM classification, were treated with a...

journal_title：Clinical neuropharmacology

authors： Kemali D

更新日期：1989-01-01 00:00:00

abstract：:Recent reports suggest some utility for famotidine, a histamine type 2 (H2) antagonist, in the treatment of schizophrenia. The current report describes a treatment-resistant patient with chronic undifferentiated schizophrenia whose most dramatic symptomatic improvements were temporarily related to the open-label addit...

journal_title：Clinical neuropharmacology

authors： Rosse RB,Kendrick K,Tsui LC,Fay-McCarthy M,Collins JP Jr,Rosenberg P,Wyatt RJ,Deutsch SI

更新日期：1995-08-01 00:00:00

abstract：:The long-term effects of mesulergine, a new drug with dopamine agonistic properties, were studied in 28 patients with Parkinson's disease. In 18 patients with late side effects of levodopa, the addition of mesulergine (10.9 mg/day) induced significant decreases in the global (-48%), rigidity (-62%), and akinesia (-37%...

journal_title：Clinical neuropharmacology

authors： Rascol A,Montastruc JL,Rascol O,Senard JM

更新日期：1986-01-01 00:00:00

abstract：OBJECTIVE:To review the current evidence on the effectiveness of second-generation antipsychotics (SGAs) in the treatment of tardive dystonia (TDt) and give recommendations for treatment. METHODS:Medline/PubMed/Psyclit/Embase database searches were conducted in January 2015, and a manual review of references within th...

journal_title：Clinical neuropharmacology

authors： Pinninti NR,Faden J,Adityanjee A

更新日期：2015-09-01 00:00:00

abstract：OBJECTIVE:The purpose of this study is to investigate the safety and efficacy of aripiprazole in first-episode drug-naive patients with schizophrenia. METHODS:A total of 45 patients were enrolled in an open-label 12-week study. Dosing was determined by clinical judgment. The main efficacy measure was the Brief Psychia...

journal_title：Clinical neuropharmacology

authors： Takahashi H,Oshimo T,Ishigooka J

更新日期：2009-05-01 00:00:00